HK1225741A1 - 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制 - Google Patents

用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制

Info

Publication number
HK1225741A1
HK1225741A1 HK16113934A HK16113934A HK1225741A1 HK 1225741 A1 HK1225741 A1 HK 1225741A1 HK 16113934 A HK16113934 A HK 16113934A HK 16113934 A HK16113934 A HK 16113934A HK 1225741 A1 HK1225741 A1 HK 1225741A1
Authority
HK
Hong Kong
Prior art keywords
inhibition
treatment
acute vascular
activation
complement
Prior art date
Application number
HK16113934A
Other languages
English (en)
Inventor
Bill N C Sun
Michael S C Fung
Cecily Sun
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1225741A1 publication Critical patent/HK1225741A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
HK16113934A 2000-10-10 2016-12-07 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制 HK1225741A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23930900P 2000-10-10 2000-10-10

Publications (1)

Publication Number Publication Date
HK1225741A1 true HK1225741A1 (zh) 2017-09-15

Family

ID=22901599

Family Applications (3)

Application Number Title Priority Date Filing Date
HK10102519.6A HK1134508A1 (zh) 2000-10-10 2010-03-10 抑制 型內皮細胞活化的抗 抗體
HK15111863.4A HK1211043A1 (zh) 2000-10-10 2015-12-02 用於治療和預防延遲異種移植或急性血管排斥反應的補體 激活的抑制
HK16113934A HK1225741A1 (zh) 2000-10-10 2016-12-07 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK10102519.6A HK1134508A1 (zh) 2000-10-10 2010-03-10 抑制 型內皮細胞活化的抗 抗體
HK15111863.4A HK1211043A1 (zh) 2000-10-10 2015-12-02 用於治療和預防延遲異種移植或急性血管排斥反應的補體 激活的抑制

Country Status (11)

Country Link
US (1) US6534058B2 (zh)
EP (5) EP2113516B1 (zh)
AT (1) ATE449791T1 (zh)
AU (1) AU2001296594A1 (zh)
CA (1) CA2424379C (zh)
DE (1) DE60140618D1 (zh)
DK (1) DK1325033T3 (zh)
ES (2) ES2333775T3 (zh)
HK (3) HK1134508A1 (zh)
PT (1) PT1325033E (zh)
WO (1) WO2002030985A2 (zh)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
KR20050090390A (ko) * 2002-12-02 2005-09-13 레지스턴시아 파마슈티컬스 아베 자기 ｃ５ 아미노산 단편 및 비자기 아미노산 단편을포함하는 폴리펩티드를 이용하여 염증성 질환을 치료하기위한 방법 및 물질
WO2004103288A2 (en) * 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages
US7442783B2 (en) 2004-03-01 2008-10-28 The Cbr Institute For Biomedical Research, Inc. Natural IgM antibodies and inhibitors thereof
EP2815767A1 (en) * 2004-05-14 2014-12-24 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
AU2013200223B2 (en) * 2005-11-04 2015-08-20 Genentech, Inc. Use of Complement Pathway Inhibitors to Treat Ocular Diseases
UA99591C2 (ru) * 2005-11-04 2012-09-10 Дженентек, Инк. Применение ингибиторов пути комплемента для лечения глазных болезней
PT1988882E (pt) 2006-03-02 2015-02-17 Alexion Pharma Inc Prolongamento da sobrevivência de um aloenxerto por inibição da atividade do complemento
ES2612118T3 (es) 2006-03-15 2017-05-12 Alexion Pharmaceuticals, Inc. Tratamiento de pacientes de hemoglobinuria nocturna paroxística mediante un inhibidor del complemento
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CA2662480C (en) * 2006-09-05 2016-11-08 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
SI2907827T1 (sl) 2006-11-02 2019-02-28 Genentech, Inc. Humanizirana protitelesa proti faktorju D in njihova uporaba
EP2148691B1 (en) 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
HUE026179T2 (en) 2008-08-05 2016-05-30 Novartis Ag Preparations and methods for antibodies against complement C5 protein
AU2014201433B2 (en) * 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
HUE060624T2 (hu) 2009-02-13 2023-04-28 Immunomedics Inc Sejten belüli hasítható kötést tartalmazó immunkonjugátumok
IN2012DN01663A (zh) 2009-09-16 2015-06-05 Immunomedics Inc
CA2782194C (en) 2009-12-02 2018-01-16 Immunomedics, Inc. Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
TWI654203B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
JP6024025B2 (ja) 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 少容量投与用のアロタイプ選択抗体の限外濾過濃縮
BR112013033272A2 (pt) 2011-06-22 2020-11-10 Apellis Pharmaceuticals, Inc. composição farmaceutica compreendendo um inibidor do complemento e um agente anti-th17, e usos dos mesmos
AU2012356170B2 (en) 2011-12-21 2016-06-16 Novartis Ag Compositions and methods for antibodies targeting Factor P
HUE041996T2 (hu) 2012-02-20 2019-07-29 Swedish Orphan Biovitrum Ab Publ A C5 humán komplementhez kötõdõ polipeptidek
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
CN105051057B (zh) 2012-11-15 2019-11-19 阿佩利斯制药公司 细胞反应性的、长效的或靶向的坎普他汀类似物及相关组合物和方法
JP6366111B2 (ja) 2012-12-13 2018-08-01 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 有効性の改善および毒性の減少のための、抗体およびｓｎ−３８からなるイムノコンジュゲートの投薬
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10280215B2 (en) * 2013-01-31 2019-05-07 Seoul National University R&Db Foundation Anti-C5 antibodies and methods of treating complement-related diseases
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
MY176200A (en) 2013-08-28 2020-07-24 Affibody Ab Binding polypeptides having a mutated scaffold
RU2733897C2 (ru) 2013-08-28 2020-10-09 Сведиш Орфан Биовитрум Аб (Пабл) Стабильные полипептиды, связывающиеся с с5 комплемента человека
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
SI3204018T1 (sl) 2014-10-07 2021-11-30 Immunomedics, Inc. Neoadjuvantna uporaba konjugatov protitelo-zdravilo
AU2015365167B2 (en) 2014-12-19 2021-07-29 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
US20180016327A1 (en) 2015-01-22 2018-01-18 Chugai Seiyaku Kabushiki Kaisha A Combination of Two or More Anti-C5 Antibodies and Methods of Use
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
KR102534895B1 (ko) 2016-06-14 2023-05-24 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
WO2018143266A1 (en) 2017-01-31 2018-08-09 Chugai Seiyaku Kabushiki Kaisha A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
CN116059313A (zh) 2017-04-07 2023-05-05 阿佩利斯制药有限公司 给药方案以及相关组合物和方法
US11365265B2 (en) 2017-12-13 2022-06-21 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
CN112512563A (zh) 2018-08-01 2021-03-16 中外制药株式会社 用于治疗或预防c5相关疾病的药物组合物和治疗或预防c5相关疾病的方法
JP7437260B2 (ja) 2019-07-31 2024-02-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン
CN114929273A (zh) 2019-07-31 2022-08-19 豪夫迈·罗氏有限公司 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
CN111171149B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的人源化单链抗体及其应用
CN115667925A (zh) 2020-05-15 2023-01-31 阿雷克森制药公司 使用细胞外囊泡来检测补体激活的方法以及其用于评估和/或监测补体介导的疾病的治疗的用途
CN114149501B (zh) * 2020-12-11 2023-05-26 天士力生物医药股份有限公司 抗c5抗体及其应用
EP4342497A1 (en) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antibody having reduced binding affinity for antigen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5506247A (en) 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5679546A (en) 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
WO1995025540A1 (en) * 1994-03-23 1995-09-28 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US5546808A (en) 1994-09-06 1996-08-20 Harris Instrument Corporation Apparatus and method for binocular measurement system
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
WO1997033603A1 (en) 1996-03-13 1997-09-18 Trustees Of The University Of Pennsylvania Novel peptides which inhibit complement activation
WO1998046248A1 (en) 1997-04-14 1998-10-22 Anderson Byron E Method and material for inhibiting complement
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
CA2302317A1 (en) 1997-08-26 1999-03-04 Gliatech, Inc. A process for inhibiting complement activation via the alternative pathway

Also Published As

Publication number Publication date
WO2002030985A3 (en) 2002-12-05
EP3031827A1 (en) 2016-06-15
WO2002030985A2 (en) 2002-04-18
EP1325033A2 (en) 2003-07-09
HK1134508A1 (zh) 2010-04-30
US6534058B2 (en) 2003-03-18
EP2113516A1 (en) 2009-11-04
CA2424379C (en) 2013-10-01
EP2281840A3 (en) 2012-05-23
EP2113516B1 (en) 2014-05-21
ATE449791T1 (de) 2009-12-15
DK1325033T3 (da) 2010-04-06
ES2483991T3 (es) 2014-08-08
CA2424379A1 (en) 2002-04-18
DE60140618D1 (de) 2010-01-07
EP1325033B1 (en) 2009-11-25
PT1325033E (pt) 2010-04-15
US20020041875A1 (en) 2002-04-11
ES2333775T3 (es) 2010-03-01
AU2001296594A1 (en) 2002-04-22
HK1211043A1 (zh) 2016-05-13
EP2281840A2 (en) 2011-02-09
EP2896631A1 (en) 2015-07-22

Similar Documents

Publication Publication Date Title
HK1225741A1 (zh) 用於治療和預防異種移植或急性血管排斥反應的補體c5激活的抑制
CY1108663T1 (el) Αναστολεις της ενεργοποιησης συμπληρωματος
NO2006008I2 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
WO2001070818A8 (en) Anti-c2/c2a inhibitors of complement activation
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
NZ611387A (en) Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
KR960704576A (ko) CD40에 대한 항체(Antibodies to CD40)
NZ596723A (en) Human antibodies that bind human il-12 and methods for producing
NZ568403A (en) CD20-specific antibodies and methods of employing same
WO2004032868A3 (en) Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
HK1134303A1 (zh) 片段文庫及其使用方法
EP1112085A4 (en) ANTI-THROMBOTIC AGENT AND HUMANIZED MONOCLONAL ANTIBODY AGAINST VON-WILLEBRAND FACTOR
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
DE69922834D1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
UA41984C2 (uk) Спосіб інгібування утворення тромбів у людини (варіанти), спосіб лікування людини для зниження у людини небезпеки постхірургічних тромботичних ускладнень (варіанти),спосіб лікування тромботичного судинного захворювання у людини (варіанти), фармацевтична композиція, що містить некон'юговане антифібринове моноклональне антитіло мн-1, фармацевтична композиція, що містить некон'югований фрагмент або похідне антифібринового моноклонального антитіла мн-1, набір для лікування людини, що потребує інгібування утворення тромбу
WO2002094194A3 (en) Compositions and methods for inhibiting metastasis
IL139571A0 (en) A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same
WO2002094376A3 (en) Compositions and methods for promoting or inhibiting ndpk